DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2005/0065158A1 Naylor Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2005/0065158A1 Naylor Et Al US 2005OO65158A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0065158A1 Naylor et al. (43) Pub. Date: Mar. 24, 2005 (54) TREATMENT OF SEXUAL DYSFUNCTION (30) Foreign Application Priority Data (75) Inventors: Alasdair Mark Naylor, Kent (GB); Pieter Hadewijn Van Der Graaf, Kent Jul. 16, 2003 (GB)......................................... O316673.3 (GB); Christopher Peter Wayman, Aug. 1, 2003 (GB). ... O318095.7 Kent (GB) Sep. 11, 2003 (GB)......................................... O321308.9 Correspondence Address: PFIZER INC. Publication Classification PATENT DEPARTMENT, MS8260-1611 EASTERN POINT ROAD (51) Int. Cl." ............................................ A61K 31/519 GROTON, CT 06340 (US) (52) U.S. Cl. ................................... 514/252.16; 514/262.1 (73) Assignee: Pfizer Inc. (21) Appl. No.: 10/883,622 (57) ABSTRACT (22) Filed: Jul. 1, 2004 This invention relates to the use of cyclic guanosine 3', Related U.S. Application Data 5'-monophosphate phosphodiesterase type five (PDE5) inhibitors, in combination with 5HT1a agonists for the (60) Provisional application No. 60/512,030, filed on Oct. treatment of Sexual dysfunction, particularly female Sexual 17, 2003. Provisional application No. 60/513,125, arousal disorder (FSAD) with concomitant hypoactive filed on Oct. 21, 2003. sexual desire disorder (HSDD). US 2005/0065158A1 Mar. 24, 2005 TREATMENT OF SEXUAL DYSFUNCTION 0009 FOD-Persistent or recurrent delay in, or absence of, orgasm following a normal Sexual CROSS-REFERENCE TO RELATED excitement phase. Women exhibit wide variability in APPLICATION the type or intensity of Stimulation that triggers orgasm. The diagnosis of FOD should be based on 0001. This application claims priority from United King the clinician's judgement that the woman's orgasmic dom Application Number 0316673.3, filed on Jul. 16, 2003, capacity is less than would be reasonable for her age, United Kingdom Application Number 0318095.7, filed on Sexual experience, and the adequacy of the Sexual Aug. 1, 2003, United Kingdom Application Number Stimulation she receives. 0321308.9, filed on Sep. 11, 2003 and the benefit from U.S. Provisional Application No. 60/512,030, filed on Oct. 17, 0010 Sexual Pain Disorders such as Dyspareunia 2003 and U.S. Provisional Application No. 60/513,125, filed and Vaginismus. Dyspareunia is the recurrent or on Oct. 21, 2003. persistent genital pain associated with Sexual inter course. Vaginismus is the recurrent or persistent 0002 This invention relates to the use of cyclic gua involuntary Spasm of the musculature of the outer nosine 3', 5'-monophosphate phosphodiesterase type five third of the vagina that interferes with sexual inter (PDE5) inhibitors, in combination with 5HT1a agonists for COSC. the treatment of Sexual dysfunction, particularly female 0011 More recently the American Foundation for Uro sexual arousal disorder (FSAD) with concomitant hypoac logic Disease has developed definitions using the same four tive sexual desire disorder (HSDD). classes (see The Journal of Urology, 2000, Vol 163, page 0.003 Male sexual dysfunction includes male erectile 888-893). The definitions are along similar lines as follows dysfunction, ejaculatory disorderS Such as premature ejacu to DSM-IV: lation (PE), anorgasmia (inability to achieve orgasm) and 0012 HSDD is the persistent or recurrent deficiency desire disorderS Such as hypoactive Sexual desire disorder (or absence) of Sexual fantasies/thoughts, and/or (lack of interest in sex). desire for or receptivity to Sexual activity, which 0004 The categories of female sexual dysfunction (FSD) causes personal distress. are best defined by contrasting them to the phases of normal female Sexual response: desire, arousal and orgasm (see S R 0013 FSAD is the persistent or recurrent inability to Leiblum, (1998), Definition and Classification of Female attain or maintain Sufficient Sexual eXcitement, caus Sexual Disorders, Int. J. Impotence Res., 10, S104-S106). ing personal distress, which may be expressed as a Desire or libido is the drive for sexual expression. Its lack of Subjective excitement, or genital (lubrication/ manifestations often include Sexual thoughts either when in Swelling) or other Somatic responses. the company of an interested partner or when exposed to 0014 FOD is the persistent or recurrent difficulty, other erotic Stimuli. Arousal includes the vascular response delay in or absence of attaining orgasm following to Sexual Stimulation, an important component of which is Sufficient Sexual Stimulation and arousal, which genital engorgement and increased vaginal lubrication, elon causes personal distress. gation of the vagina and increased genital Sensation/sensi tivity and a Subjective eXcitement response. Orgasm is the 0015 Sexual pain disorders: Dyspareunia is the release of Sexual tension that has culminated during arousal. recurrent or persistent genital pain associated with Hence, FSD occurs when a woman has an absent, inad Sexual intercourse. Vaginismus is the recurrent or equate or unsatisfactory response in any one or more of these persistent involuntary Spasm of the musculature of phases, usually desire, arousal or orgasm. the outer third of the vagina that interferes with vaginal penetration, which causes personal distreSS. 0005 The American Psychiatric Association classifies 0016 HSDD is present if a woman has no or little desire female sexual dysfunction (FSD) into four classes: FSAD, to be sexual, and has no or few Sexual thoughts or fantasies. hypoactive sexual desire disorder (HSDD), female orgasmic This type of FSD can be caused by low testosterone levels, disorder (FOD), and sexual pain disorders (e.g. dyspareunia due either to natural menopause or to Surgical menopause. and vaginismus) see the American Psychiatric ASSocia Other causes in both pre-menopausal woman (i.e. woman tion's Diagnostic and Statistical Manual of Mental Disor who are pre-menopausal and who have not have hysterec ders, 4th Edition (DSM-IV)). tomies) as well as post menopausal women include illness, 0006 DSM-IV defines the four classes as follows: medications, fatigue, depression and/or anxiety. Factors having a potential (conscious or Sub-conscious) psychologi 0007 HSDD-Persistently or recurrently deficient cal impact Such as relationship difficulties or religious (or absent) Sexual fantasies and desire for Sexual factors may be related to the presence of/development of activity which causes marked distreSS or interper HSDD in females. Sonal difficulties. The judgement of deficiency or absence is made by the clinician, taking into account 0017 FSAD is a highly prevalent sexual disorder affect factors that affect functioning, Such as age and the ing pre-, peri-, and post menopausal women. It is associated context of the perSons life. with concomitant disorderS Such as depression, cardiovas cular diseases, diabetes and UG disorders. FSAD is charac 0008 FSAD-Persistent or recurrent inability to terised by inadequate genital response to Sexual Stimulation. attain, or to maintain until completion of the Sexual The genitalia do not undergo the engorgement that charac activity, an adequate lubrication-Swelling response terises normal Sexual arousal. The Vaginal walls are poorly of Sexual excitement. lubricated, So that intercourse is painful. Orgasms may be US 2005/0065158A1 Mar. 24, 2005 impeded. FSAD can be caused by reduced oestrogen at 0029. In an embodiment of the invention, the female menopause or after childbirth and during lactation, as well Subject is oestrogen and androgen replete. Replete levels of as by illnesses, with vascular components Such as diabetes the oestrogen and androgen may already exist in the Subject and atherosclerosis. Other causes result from treatment with or they may be achieved artificially. Replete levels or diuretics, antihistamines, antidepressants e.g. Selective Sero Oestrogen may be achieved artificially by administration of tonin reuptake inhibitors or antihypertensive agents. estradiol, estrone, estriol, a synthetic oestrogen (for example 0018 Sexual pain disorders (includes dyspareunia and Oestrogen benzoate), an agent which causes the body to vaginismus) are characterised by pain resulting from pen produce oestrogen and/or an oestrogen receptor modulator/ etration and Sexual activity and may be caused by medica agonist (for example raloxifene or lasofoxifene). Replete tions which reduce lubrication, endometriosis, pelvic levels of androgen may be achieved by administration of an inflammatory disease, inflammatory bowel disease or uri androgen (Such as include androsterone, dehydro-androster nary tract problems. one, testosterone, androstanedione or a synthetic androgen), an agent which causes the body to produce androgen and/or 0019 We have now found that PDE5 inhibitors in com bination with 5HT1a agonists work well in treating subjects androgen receptor modulator/agonist (for example tibolone) who suffer from sexual dysfunction. The combination may 0030 AS used herein the term replete means having be deemed Synergistic. concentrations of Oestrogen and androgen equal to or greater 0020 Suitable sexual dysfunctions include FSAD, than minimum physiological concentrations found in a nor HSDD and FOD in women and MED in men. mal Subject. 0021 We have found that PDE5 inhibitors in combina 0031 Oestrogen is the general term for any substance tion with 5HT1a agonists work particularly well in FSAD having the physiological activity of oestradiol. It includes subjects who suffer from concurrent significant HSDD. The
Load more

Recommended publications
  • An Introduction to Medicinal
    An Introduction to Medicinal Chemistry FIFTH EDITION Graham L. Patrick 1 Patrick97397.indb iii 11/28/2012 9:11:45 PM 1 Great Clarendon Street, Oxford, OX2 6DP, United Kingdom Oxford University Press is a department of the University of Oxford. It furthers the University’s objective of excellence in research, scholarship, and education by publishing worldwide. Oxford is a registered trade mark of Oxford University Press in the UK and in certain other countries © Graham L. Patrick 2013 Th e moral rights of the author have been asserted Second Edition copyright 2001 Th ird Edition copyright 2005 Fourth Edition copyright 2009 Impression: 1 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing of Oxford University Press, or as expressly permitted by law, by licence or under terms agreed with the appropriate reprographics rights organization. Enquiries concerning reproduction outside the scope of the above should be sent to the Rights Department, Oxford University Press, at the address above You must not circulate this work in any other form and you must impose this same condition on any acquirer British Library Cataloguing in Publication Data Data available ISBN 978–0–19–969739–7 Printed in Italy by L.E.G.O. S.p.A.—Lavis TN Links to third party websites are provided by Oxford in good faith and for information only. Oxford disclaims any responsibility for the materials contained in any third party website referenced in this work.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Pharmacokinetics and Related Topics
    Pharmacokinetics and 11 related topics 11.1 The three phases of drug may be absorbed through the mucosal membranes of the mouth, but most passes down into the stomach where action it encounters gastric juices and hydrochloric acid. Th ese chemicals aid in the digestion of food and will treat a Th ere are three phases involved in drug action. Th e drug in a similar fashion if it is susceptible to breakdown fi rst of these is the pharmaceutical phase . For an orally and is not protected within an acid-resistant pill or cap- administered drug, this includes the disintegration of a sule. For example, the fi rst clinically useful penicillin was pill or capsule in the gastrointestinal tract (GIT), the broken down in the stomach and had to be administered release of the drug, and its dissolution. Th e pharmaceu- by injection. Other acid-labile drugs include the local tical phase is followed by the pharmacokinetic phase , anaesthetics and insulin . If the drug does survive the which includes absorption from the GIT into the blood stomach, it enters the upper intestine where it encoun- supply, and the various factors that aff ect a drug’s survival ters digestive enzymes that serve to break down food. and progress as it travels to its molecular target. Th e fi nal Assuming the drug survives this attack, it then has to pharmacodynamic phase involves the mechanism by pass through the cells lining the gut wall. Th is means that which a drug interacts with its molecular target and the it has to pass through a cell membrane on two occasions: resulting pharmacological eff ect.
    [Show full text]
  • Providing for Duty-Free Treatment for Specified Pharmaceutical Active
    13 . 3 . 97 I EN I Official Journal of the European Communities No L 71 / 1 I (Acts whose publication is obligatory) COUNCIL REGULATION (EC) No 467/97 of 3 March 1997 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an 'international non-proprietary name' (INN) from the World Health Organization and specified products used for the manufacture of finished pharmaceuticals and withdrawing duty-free treatment as pharmaceutical products from certain INNs whose predominant use is not pharmaceutical THE COUNCIL OF THE EUROPEAN UNION , whereas in the context of the review it was concluded that it was appropriate to rectify the situation with regard Having regard to the Treaty establishing the European to certain INNs whose use was predominantly non­ Community, and in particular Article 113 thereof, pharmaceutical and which had been inadvertently included among those INNs already receiving duty-free treatment, Having regard to the proposal from the Commission , Whereas, in the course of the Uruguay Round negotia­ HAS ADOPTED THIS REGULATION : tions the Community and a number of countries discussed duty-free treatment of pharmaceutical products ; Article 1 Whereas the participants in those discussions concluded that in addition to products falling within the Harm­ From 1 April 1997 the Community shall also accord onized System (HS) Chapter 30 and HS headings 2936 , duty-free treatment for the INNs listed in Annex I as well 2937, 2939 and 2941 , duty-free treatment should be given as the salts, esters and hydrates of such products . to designated pharmaceutical active ingredients bearing an 'international non-proprietary name' (INN) from the Article 2 World Health Organization as well as specified salts , esters and hydrates of such INNs, and also to designated From 1 April 1997 the Community shall also grant duty­ products used for the production and manufacture of free treatment for the products used in the production finished products ; and manufacture of pharmaceutical products listed in Annex II .
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]
  • WO 2018/023009 Al 01 February 2018 (01.02.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2018/023009 Al 01 February 2018 (01.02.2018) W !P O PCT (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, C07D 417/14 (2006.01) A61K 31/496 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, A61P 25/18 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (21) International Application Number: KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, PCT/US20 17/044400 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (22) International Filing Date: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 28 July 2017 (28.07.2017) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 62/368,630 29 July 2016 (29.07.2016) US UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (71) Applicant: CONCERT PHARMACEUTICALS, INC.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2015) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2015) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.468,627 B2 Jacobsen Et Al
    USOO9468627B2 (12) United States Patent (10) Patent No.: US 9.468,627 B2 Jacobsen et al. (45) Date of Patent: Oct. 18, 2016 (54) SLOW-RELEASE FORMULATIONS OF FOREIGN PATENT DOCUMENTS 5-HYDROXYTRYPTOPHANAS AN ADJUNCT TO PRO-SEROTONERGIC THERAPES EP 1 637 185 A1 3, 2006 WO WO 2005/112906 * 1 2005 (71) Applicant: Duke University. Durham, NC (US) WO WO 2005/112906 A2 12/2005 WO WO 2009/042632 A2 4/2009 (72) Inventors: Jacob P. R. Jacobsen, Durham, NC WO WO 2009/043834 * 4/2009 (US); Marc G. Caron, Hillsborough, WO WO 2009/043834 A1 4/2009 NC (US) WO WO 2011/077406 A2 6, 2011 WO WO 2012/O54815 A1 4/2012 (73) Assignee: Duke University. Durham, NC (US) (*) Notice: Subject to any disclaimer, the term of this OTHER PUBLICATIONS patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. International Search Report and Written Opinion, PCT/US2011/ 057247, mailed Feb. 28, 2012. (21) Appl. No.: 13/866,145 5HTP: MedlinePlus Supplements. U.S. National Library of Medi cation. NIH National Institutes of Health. http://www.nlm.nih.gov/ (22) Filed: Apr. 19, 2013 medlineplus/drug info/natural/794.html. 4 pages, retrieved Aug. 25. (65) Prior Publication Data 2012. Alino; J1-I et al. “5-hydroxytryptophan (5-HTP) and a MAOI US 2013/0230577 A1 Sep. 5, 2013 (nialamide)in the treatment of depressions' Int. Pharmacophychiat. 1976; 11: 8-15. Related U.S. Application Data Grabowski et al. “Fluoxetine Is Ineffective for Treatment of Cocaine (63) Continuation of application No. Dependence or Concurrent Opiate and Cocaine Dependence: Two Placebo-Controlled, Double-Blind Trials' Journal of Clinical PCT/US2011/057247, filed on Oct.
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]